Skip to content

Study · In vitro (cells) · rat · 2001

10 results

Regulation of Pit-1 expression by ghrelin and GHRP-6 through the GH secretagogue receptor.

García A, Alvarez CV, Smith RG, Diéguez C

Molecular endocrinology (Baltimore, Md.)1 Sept 2001Cited by 70 (Europe PMC)

PMID11518797 (opens in a new tab)DOI10.1210/mend.15.9.0694 (opens in a new tab)PepBankPUB-11518797
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In infant rat pituitary cells, GHRP‑6 activated pit-1 expression in a time- and dose-dependent manner.

    In plain wordsIn cells from infant rats, GHRP‑6 increased pit-1 expression with effects that depended on time and dose.

    Peptide
    GHRP-6
    Outcome
    IncreasePit-1 expression
    Study

    ratn: not reported in source

    infant rat anterior pituitary cells
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    By a combination of Northern and Western blot analysis we found that GHRP-6 elicits a time- and dose-dependent activation of pit-1 expression in monolayer cultures of infant rat anterior pituitary cells.
  2. 02LabIn vitro (cells)Mechanism

    In HEK293-GHS-R cells, GHRP‑6 stimulated luciferase expression driven by the pit-1 promoter region.

    In plain wordsIn cells, GHRP‑6 increased luciferase expression controlled by the pit-1 promoter.

    Peptide
    GHRP-6
    Outcome
    IncreasePit-1 promoter-driven luciferase expression
    Study

    n: not reported in source

    HEK293-GHS-R cells
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Using an established cell line (HEK293-GHS-R) that overexpresses the GH secretagogue receptor, we showed a marked stimulatory effect of GHRP-6 on the pit-1 -2,500 bp 5'-region driving luciferase expression.
  3. 03LabIn vitro (cells)Mechanism

    In the cell experiments, GHRP‑6-induced pit-1 promoter activation depended on PKC activation.

    In plain wordsIn cells, GHRP‑6-induced pit-1 promoter activation depended on PKC.

    Peptide
    GHRP-6
    Outcome
    Not applicablePKC dependence
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The effect was dependent on PKC, MAPK kinase, and PKA activation.
    1 context sentence
    Summary · context
    We truncated the responsive region to -231 bp, a sequence that contains two CREs, and found that both CREs are needed for GHRP-6-induced transcriptional activation in both HEK293-GHS-R cells and infant rat anterior pituitary primary cultures.
  4. 04LabIn vitro (cells)Mechanism

    In the cell experiments, GHRP‑6-induced pit-1 promoter activation depended on MAPK kinase activation.

    In plain wordsIn cells, GHRP‑6-induced pit-1 promoter activation depended on MAPK kinase.

    Peptide
    GHRP-6
    Outcome
    Not applicableMAPK kinase dependence
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The effect was dependent on PKC, MAPK kinase, and PKA activation.
    1 context sentence
    Summary · context
    We truncated the responsive region to -231 bp, a sequence that contains two CREs, and found that both CREs are needed for GHRP-6-induced transcriptional activation in both HEK293-GHS-R cells and infant rat anterior pituitary primary cultures.
  5. 05LabIn vitro (cells)Mechanism

    In the cell experiments, GHRP‑6-induced pit-1 promoter activation depended on PKA activation.

    In plain wordsIn cells, GHRP‑6-induced pit-1 promoter activation depended on PKA.

    Peptide
    GHRP-6
    Outcome
    Not applicablePKA dependence
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The effect was dependent on PKC, MAPK kinase, and PKA activation.
    1 context sentence
    Summary · context
    We truncated the responsive region to -231 bp, a sequence that contains two CREs, and found that both CREs are needed for GHRP-6-induced transcriptional activation in both HEK293-GHS-R cells and infant rat anterior pituitary primary cultures.

Studies that did not test the peptide alone5

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

  1. 06LabNot a test of GHRP-6 aloneIn vitro (cells)Mechanism

    In infant rat pituitary cells, actinomycin D blocked GHRP‑6-induced pit-1 activation.

    In plain wordsIn cells from infant rats, actinomycin D blocked GHRP‑6-induced pit-1 activation.

    Peptide
    GHRP-6
    Outcome
    DecreasePit-1 activation with actinomycin D
    Study

    ratn: not reported in source

    infant rat anterior pituitary cells
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    This effect was blocked by pretreatment with actinomycin D, but not by cycloheximide, suggesting that this action was due to direct transcriptional activation of pit-1.
    1 context sentence
    Summary · context
    By a combination of Northern and Western blot analysis we found that GHRP-6 elicits a time- and dose-dependent activation of pit-1 expression in monolayer cultures of infant rat anterior pituitary cells.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  2. 07LabNot a test of GHRP-6 aloneIn vitro (cells)Mechanism

    In infant rat pituitary cells, cycloheximide did not block GHRP‑6-induced pit-1 activation.

    In plain wordsIn cells from infant rats, cycloheximide did not block GHRP‑6-induced pit-1 activation.

    Peptide
    GHRP-6
    Outcome
    No significant changePit-1 activation with cycloheximide
    Study

    ratn: not reported in source

    infant rat anterior pituitary cells
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    This effect was blocked by pretreatment with actinomycin D, but not by cycloheximide, suggesting that this action was due to direct transcriptional activation of pit-1.
    1 context sentence
    Summary · context
    By a combination of Northern and Western blot analysis we found that GHRP-6 elicits a time- and dose-dependent activation of pit-1 expression in monolayer cultures of infant rat anterior pituitary cells.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  3. 08LabNot a test of GHRP-6 aloneIn vitro (cells)Mechanism

    In HEK293-GHS-R cells, both CREs in the truncated pit-1 promoter were required for GHRP‑6-induced transcriptional activation.

    In plain wordsIn cells, both CRE sites in the truncated promoter were needed for GHRP‑6-induced pit-1 activation.

    Peptide
    GHRP-6
    Outcome
    Not applicableCRE requirement in HEK293-GHS-R cells
    Study

    n: not reported in source

    HEK293-GHS-R cells with truncated promoter
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    We truncated the responsive region to -231 bp, a sequence that contains two CREs, and found that both CREs are needed for GHRP-6-induced transcriptional activation in both HEK293-GHS-R cells and infant rat anterior pituitary primary cultures.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  4. 09LabNot a test of GHRP-6 aloneIn vitro (cells)Mechanism

    In infant rat pituitary cultures, both CREs in the truncated pit-1 promoter were required for GHRP‑6-induced transcriptional activation.

    In plain wordsIn cells from infant rats, both CRE sites were needed for GHRP‑6-induced pit-1 activation.

    Peptide
    GHRP-6
    Outcome
    Not applicableCRE requirement in primary pituitary cells
    Study

    ratn: not reported in source

    infant rat anterior pituitary cells
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    We truncated the responsive region to -231 bp, a sequence that contains two CREs, and found that both CREs are needed for GHRP-6-induced transcriptional activation in both HEK293-GHS-R cells and infant rat anterior pituitary primary cultures.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  5. 10LabNot a test of GHRP-6 aloneIn vitro (cells)Mechanism

    In cells, pCMV-pit-1 coexpression potentiated the GHRP‑6 effect on the pit-1 promoter.

    In plain wordsIn cells, extra Pit-1 expression strengthened the GHRP‑6 effect on the pit-1 promoter.

    Peptide
    GHRP-6
    Outcome
    IncreasePromoter activation after Pit-1 coexpression
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    Increasing Pit-1 by coexpression of pCMV-pit-1 potentiated the GHRP-6 effect on the pit-1 promoter.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.